397328-86-8Relevant articles and documents
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
Kozikowski, Alan P.,Shen, Sida,Pardo, Marta,Tavares, Maurício T.,Szarics, Dora,Benoy, Veronick,Zimprich, Chad A.,Kutil, Zsófia,Zhang, Guiping,Ba?inka, Cyril,Robers, Matthew B.,Van Den Bosch, Ludo,Eubanks, James H.,Jope, Richard S.
, p. 1679 - 1695 (2019/01/04)
Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological a
PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
-
Paragraph 0265; 0266, (2015/11/25)
In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
-
Page/Page column 67, (2012/08/27)
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
